Overall survival (os) of patients (pts) with relapsed and refractory multiple myeloma (rrmm): Adjusting for crossover in the mm-003 trial for pomalidomide plus low-dose dexamethasone (pom + lodex) vs. High-dose dexamethasone (hidex)
Authors:
Morgan G, San Miguel J, Dhanasiri S, Lee D, Palumbo A, Facon T, Zaki M, Yu X, Sternas L, Jacques C, Weisel K, Offner F and Dimopoulos M.
Publication Type:
Conference Proceedings – Poster
Publication Name:
19th Congress of European Hematology Association
Citation:
Morgan G, San Miguel J, Dhanasiri S, Lee D, Palumbo A, Facon T, Zaki M, Yu X, Sternas L, Jacques C, Weisel K, Offner F and Dimopoulos M. Overall survival (os) of patients (pts) with relapsed and refractory multiple myeloma (rrmm): Adjusting for crossover in the mm-003 trial for pomalidomide plus low-dose dexamethasone (pom + lodex) vs. High-dose dexamethasone (hidex) 19th Congress of European Hematology Association. Milan, Italy. 12-15 June 2014. Poster.
